The site of cutaneous infection influences the immunological response and clinical outcome of hamsters infected with Leishmania panamensis

Parasite Immunology

Volumn 25, Issue 3, 2003, Pages 139-148

  Osorio, Yaneth ^a   Melby, Peter C ^b,c   Pirmez, Claude ^d   Chandrasekar, Bysani ^c   Guarín, Nora ^a   Travi, Bruno L ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cutaneous leishmaniasis; Cytokines; Immunity; Leishmania panamensis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MEGLUMINE ANTIMONATE; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BODY BURDEN; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; EXPERIMENTAL INFECTION; FACE; FEMALE; FOOT; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATORY INFILTRATE; LEISHMANIA PANAMENSIS; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN CELL; SYRIAN HAMSTER; TISSUE NECROSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; INTERFERON TYPE I; LEISHMANIA GUYANENSIS; LEISHMANIASIS, MUCOCUTANEOUS; SKIN DISEASES;

ANIMALIA; CRICETINAE; LEISHMANIA PANAMENSIS; MESOCRICETUS AURATUS; PROTOZOA;

EID: 0348140690     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.2003.00615.x     Document Type: Article

References (58)

1. Titus RG & Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-1308.
2. Lainson R & Strangways-Dixon J. Leishmania mexicana: The epidemiology of dermal leishmaniasis in British Honduras. Trans R Soc Trop Med Hyg 1963; 57: 242-265.
3. Llanos-Cuentas EA, Marsden PD, Cuba CC, Barreto AC & Campos M. Possible risk factors in development of mucosal lesions in leishmaniasis. Lancet 1984; 2: 295.
4. Kirkpatrick CE, Nolan TJ & Farrell JP. Rate of Leishmania-induced skin-lesion development in rodents depends on the site of inoculation. Parasitology 1987; 94: 451-465.
5. Nabors GS & Farrell JP. Site-specific immunity to Leishmania major in SWR mice: the site of infection influences susceptibility and expression of the antileishmanial immune response. Infect Immun 1994; 62: 3655-3662.
6. Nabors GS, Nolan T, Croop W, Li J & Farrell JP. The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c x C57BL/6), F1 mice infected with Leishmania major. Parasite Immunol 1995; 17: 569-579.
7. Rey JA, Travi BL, Valencia AZ & Saravia NG. Infectivity of the subspecies of the Leishmania braziliensis complex in vivo and in vitro. Am J Trop Med Hyg 1990; 43: 623-631.
8. Melby PC, Chandrasekar B, Zhao W & Coe JE. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like response. J Immunol 2001; 166: 1912-1920.
9. Melby PC, Tryon VV, Chandrasekar B & Freeman GL. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 1998; 66: 2135-2142.
10. Travi BL, Martinez JE & Zea A. Antimonial treatment of hamsters infected with Leishmania (Viannia) panamensis: assessment of parasitological cure with different therapeutic schedules. Trans R Soc Trop Med Hyg 1993; 87: 567-569.
11. Kahl LP, Byram JE, David JR, Comerford SA & Von Lichtenberg F. Leishmania (Viannia) braziliensis: comparative pathology of golden hamsters infected with isolates from cutaneous and mucosal lesions of patients residing in Tres Bracos, Bahia, Brazil. Am J Trop Med Hyg 1991; 44: 218-232.
12. Low-A-Chee RM, Rose P & Ridley DS. An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983; 77: 255-260.
13. Melby PC, Kreutzer RD, McMahon-Pratt D, Gam AA & Neva FA. Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis 1992; 15: 924-937.
14. Marsden PD, Lessa HA, Oliveira MR et al. Clinical observations of unresponsive mucosal leishmaniasis. Am J Trop Med Hyg 1998; 59: 543-545.
15. Gutierrez Y, Salinas GH, Palma G, Valderrama LB, Santrich CV & Saravia NG. Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection. Am J Trop Med Hyg 1991; 45: 281-289.
16. Sato N, Ahuja SK, Quinones M et al. CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation. J Exp Med 2000; 192: 205-218.
17. Tacchini-Cottier F, Zweifel C, Belkaid Y et al. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major. J Immunol 2000; 165: 2628-2636.
18. Castes M, Agnelli A & Rondon AJ. Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis. Clin Exp Immunol 1984; 57: 279-286.
19. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL & Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994; 152: 5949-5956.
20. Carvalho EM, Teixeira RS & Johnson WD Jr. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 1981; 33: 498-500.
21. Caceres-Dittmar G, Tapia FJ, Sanchez MA et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91: 500-505.
22. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV & Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62: 837-842.
23. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F & Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis [see comments]. J Clin Invest 1993; 91: 1390-1395.
24. Nabors GS & Farrell JP. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect Immun 1994; 62: 5498-5504.
25. Nabors GS & Farrell JP. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody. Am J Trop Med Hyg 1995; 53: 55-60.
26. Noben-Trauth N, Paul WE & Sacks DL. IL-4-and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 1999; 162: 6132-6140.
27. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL & Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
28. Heinzel FP, Sadick MD, Mutha SS & Locksley RM. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991; 88: 7011-7015.
29. Travi BL, Osorio Y, Melby PC, Chandrasekar B, Arteaga L & Saravia NG. Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. Infect Immun 2002; 70: 2288-2296.
30. Gazzinelli RT, Oswald IP, James SL & Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 1992; 148: 1792-1796.
31. Bogdan C, Vodovotz Y & Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549-1555.
32. Vieth M, Will A, Schroppel K, Rollinghoff M & Gessner A. Interleukin-10 inhibits antimicrobial activity against Leishmania major in murine macrophages. Scand J Immunol 1994; 40: 403-409.
33. Vouldoukis I, Becherel PA, Riveros-Moreno V et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 1997; 27: 860-865.
34. Louzir H, Melby PC, Ben Salah A et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998; 177: 1687-1695.
35. Belkaid Y, Hoffmann KF, Mendez S et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194: 1497-1506.
36. Kane MM & Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166: 1141-1147.
37. Karp CL, el-Safi SH, Wynn TA et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]. J Clin Invest 1993; 91: 1644-1648.
38. Kenney RT, Sacks DL, Gam AA, Murray HW & Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 1998; 177: 815-818.
39. Murphy ML, Wille U, Villegas EN, Hunter CA & Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31: 2848-2856.
40. Assoian RK, Fleurdelys BE, Stevenson HC et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987; 84: 6020-6024.
41. Bogdan C & Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci 1993; 685: 713-739.
42. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ & Srimal S. Macrophage deactivating factor and transforming growth factors beta-1 beta-2 and beta-3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990; 145: 940-944.
43. Nelson BJ, Ralph P, Green SJ & Nacy CA. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor beta-1. J Immunol 1991; 146: 1849-1857.
44. Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR & Reed SG. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci USA 1993; 90: 3442-3446.
45. Li J, Hunter CA & Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 1999; 162: 974-979.
46. Barral-Netto M, Barral A, Brownell CE et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257: 545-548.
47. Scott PA & Farrell JP. Experimental cutaneous leishmaniasis. I. Nonspecific immunodepression in BALB/c mice infected with Leishmania tropica. J Immunol 1981; 127: 2395-2400.
48. Gifawesen C & Farrell JP. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 1989; 57: 3091-3096.
49. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
50. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-1050.
51. Rodrigues V Jr, Santana da Silva J & Campos-Neto A. Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis. Infect Immun 1998; 66: 1233-1236.
52. Holaday BJ, Pompeu MM, Jeronimo S et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 1993; 92: 2626-2632.
53. Ghalib HW, Piuvezam MR, Skeiky YA et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92: 324-329.
54. Conceicao-Silva F, Dorea RC, Pirmez C, Schubach A & Coutinho SG. Quantitative study of Leishmania braziliensis reactive T cells in peripheral blood and in the lesions of patients with American mucocutaneous leishmaniasis. Clin Exp Immunol 1990; 79: 221-226.
55. Coutinho SG, Pirmez C, Mendonca SCF, Conceicao-Silva F & Dorea RC. Pathogenesis and immunopathology of leishmaniasis. Mem Inst Oswaldo Cruz 1987; 82 (Suppl.): 214.
56. Pirmez C, Cooper C, Paes-Oliveira M, Schubach A, Torigian VK & Modlin RL. Immunologic responsiveness in American cutaneous leishmaniasis lesions. J Immunol 1990; 145: 3100-3104.
57. Saravia NG, Valderrama L, Labrada M et al. The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis. J Infect Dis 1989; 159: 725-735.
58. Arredondo B & Perez H. Alterations of the immune response associated with chronic experimental leishmaniasis. Infect Immun 1979; 25: 16-22.